Viewing Study NCT00004235



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004235
Status: COMPLETED
Last Update Posted: 2016-07-14
First Post: 2000-01-28

Brief Title: Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Sponsor: Alliance for Clinical Trials in Oncology
Organization: Alliance for Clinical Trials in Oncology

Study Overview

Official Title: A Phase II Study of Taxotere and Irinotecan CPT-11 in Patients With Advanced Adenocarcinoma of the Lower Esophagus Esophagogastric Junction and Gastric Cardia
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients who have advanced cancer of the esophagus or stomach
Detailed Description: OBJECTIVES I Determine the objective tumor response rate in patients with advanced adenocarcinoma of the lower esophagus esophagogastric junction and gastric cardia treated with docetaxel and irinotecan II Determine time to progression and overall survival of patients treated treated with this regimen III Determine the toxic effects of this regimen in these patients IV Assess treatment response in these patients by determining the prevalence of dysphagia anorexia and swallowing ability at diagnosis and during treatment with this regimen

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
CDR0000067479 REGISTRY PDQ Physician Data Query None